#### India Equity Research | Speciality Chemicals December 18, 2020 Company Update

# **Navin Fluorine**

Refer to important disclosures at the end of this report

# Leveraging core capabilities; growth runway improving

CMP: Rs 2,556 as of (December 17, 2020) TP: Rs 2,742 (▲) 12 months

Rating: BUY (∎)

Upside: 7.3 %

- NFIL has announced capex of Rs1.95bn for setting up a multi-purpose plant (MPP), which is expected to commence production from H1FY23. The MPP is expected to reach peak utilization levels in 2-3 years, with an asset turnover of 1.35-1.45x (Rs2.6-2.8bn sales potential). The plant is structured to act as a launchpad for upcoming molecules.
- The plant will produce five new molecules to cater to the agro space, for which there is no domestic competition. NFIL expects some of the molecules to grow significantly and would require dedicated plants in the next 2-3 years, depending on the success of the end product.
- NFIL also has a pipeline of seven new products (for pharma and agro), which would be gradually
  introduced as and when required, depending on economics of five initial molecules. NFIL sees
  the possibility of forward-integration in some molecules from the initial launch.
- Large capex undertaking for MPP ensures long-term earnings growth, in our view. We raise our TP by 17% to Rs 2,742 as we move from target PE to target PEG methodology (forward PE/1year prospective EPS growth). We apply 1.38x PEG on Dec'22E EPS and 25% growth in Dec'23E EPS. Maintain a Buy rating and OW in EAP.

Long-term project economics positive; MPP to unlock more possibilities for growth: The Rs1.95bn project is anticipated to have a payback period of ~4 years, with EBITDAM better than the current annual run rate and structural improvement in return ratios. Management expects peak utilization levels in 2-3 years post the commencement. The project would be undertaken through subsidiary Navin Fluorine Advanced Sciences, which may entail low tax rates. Civil costs are high for this MPP, although ~40% of the facility space would still remain vacant post the expansion. The structure of the plant would allow the plant to act as a launchpad for subsequent molecule launches as well as undertake backward integration. Management anticipates strong cash flows to entirely support such capex undertaking without the need for raising debt, subject to future evaluation.

**Initial target for 5 agrochemical molecules; forward-integration on the cards:** NFIL plans to produce five new molecules at this MPP, which are already commercialized (R&D and Pilot complete), to cater to the agrochemicals space. NFIL's clients are banking on the success of the end products where these molecules are used as intermediates. Management sees a volume potential of ~300-500tpa in four molecules. Some of them would even require separate dedicated facilities in 2-3 years post the commencement, subject to the success of the end product. NFIL is considering forward-integration in two of the initial five molecules to become an active ingredient supplier. NFIL has a separate pipeline of seven products (in pilot mode) for pharma and agro (50:50). They would be gradually undertaken as and when needed, subject to the market adoption of initial five molecules.

**Robust outlook; maintain Buy:** Large capex undertaking for MPP ensures earnings growth in the longer term, in our view. We bake in new project contribution in FY23, and raise our Revenue/EPS estimates by ~4%. We increase our TP by 17% to Rs2,742 as we move from target PE to target PEG methodology. We maintain a Buy rating and OW in EAP. PEG ratio has been ~1x in the last two years and we apply a ~38% premium in our PEG multiple due to lateral structural improvement in return ratios (RoE of 16% in FY22 to 22% in FY23). The key downside risk is any delay in the commissioning of the project.

Please see our sector model portfolio (Emkay Alpha Portfolio): Speciality Chemicals (Page 8) Financial Snapshot (Consolidated)

(Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	9,959	10,616	11,931	14,295	21,565
EBITDA	2,184	2,635	3,199	3,798	5,815
EBITDA Margin (%)	21.9	24.8	26.8	26.6	27.0
APAT	1,491	1,849	2,260	2,748	4,331
EPS (Rs)	30.2	37.4	45.7	55.5	87.5
EPS (% chg)	(17.2)	23.9	22.2	21.6	57.6
ROE (%)	14.5	14.9	15.1	16.2	21.7
P/E (x)	84.9	68.5	56.0	46.1	29.2
EV/EBITDA (x)	57.9	47.2	38.8	33.0	21.6
P/BV (x)	11.8	9.0	8.0	7.0	5.8



### Change in Estimates

Change in E	stimat	tes								
EPS Chg FY2	EPS Chg FY21E/FY22E (%) -/									
Target Price	change	e (%)		16.7						
Target Period	l (Mon	ths)		12						
Previous Rec	0			BUY						
Emkay vs Co	onsen	sus								
	EPS E	stimate								
			(21E	FY22E						
Emkay			45.7	55.5						
Consensus			47.0	55.4						
Mean Conser	nsus T	P (12M	)	Rs 2,331						
Stock Details	5									
Bloomberg C	ode			NFIL IN						
Face Value (I	,			2						
Shares outsta		49								
52 Week H/L		2	2,760 / 929							
M Cap (Rs br	n/USD	bn)		126 / 1.72						
Daily Avg Vol	ume (	nos.)		1,42,940						
Daily Avg Tur	nover	(US\$ n	าท)	4.6						
Shareholdin	g Patt	ern Se	p <b>'20</b>							
Promoters				30.5%						
FIIs				21.1%						
DIIs				20.3%						
Public and Of	hers			28.1%						
Price Perform	nance	•								
(%)	1M	3M	61	/ 12M						
Absolute	(2)	21	6	0 170						
Rel. to Nifty	(8)	1	1	5 139						
Relative pric	e cha	irt								
Rs ا				<b>^%</b> [ <sup>170</sup>						
2390 -			I.A. N	h // 136						



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

#### Rohit Sinha


rohit.sinha@emkayglobal.com +91 22 6612 1306

Source: Company, Emkay Research

Enkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


# Story in Charts

Exhibit 1: Strong momentum in CRAMS and Specialty business to lift growth in FY23




Source: Company, Emkay Research

# Exhibit 3: Specialty Chemicals to see double-digit growth in next three years, led by capex undertakings




Source: Company, Emkay Research

# Exhibit 5: Return ratios to improve, led by larger share of high value business





Source: Company, Emkay Research


Exhibit 2: EBITDA to improve on sustainable margin growth from high-value business





Source: Company, Emkay Research











## Key conference call highlights

- Project capex of Rs1.95bn is expected with a four-year payback period and asset turnover of 1.35-1.45x (Rs2.6-2.8bn). Peak utilization is expected in 2-3 years. EBITDA margin will be slightly better and RoCE in the similar range.
- Project entails five completely new products for which there is no domestic competition (100% agro). Three products will be domestic oriented (for further formulations and then exported), while two will focus on direct exports. Management expects some of the products to become large plays and hence, would require dedicated plants in 2-3 years post the commencement. Four products are expected to have a potential of 300-500tpa, assuming the end product picks up.
- Such five products are already commercialized (R&D and Pilot complete), and customers are banking on the success of the end products. It will involve more complex fluorination chemistry. Material supply/LOI are already in place with customers for supply. NFIL is the second vendor (not originator) for four products and originator for one product.
- The MPP (acting as a launchpad) would be structured in a way that it will allow backward integration as well. Management expects projected internal cash flows to be enough for such capex, however, it will relook going ahead. Such an undertaking has high civil costs and 40% of the area would still remain vacant for future purposes post current undertaking. After this project, total Dahej land availability will be 2/3rd of the original allocated area.
- NFIL also has a pipeline (in pilot mode) for another seven products (50:50 agro and pharma), which would be integrated as and when required from this MPP facility. In case one or more of the five initial products require a dedicated facility (successful) or do not take off as expected, they shall be replaced with the product from the pipeline. However, the MPP cannot manufacture all (5+7) 12 products together. All 12 products are intermediates or advanced intermediates. One of the seven products is a pure pharma import substitute.
- NFIL will never become an API or AI player, but for strategic reasons NFIL could forwardintegrate for specific products. It is already in discussion for two of the initial five molecules on doing the AI (forward), and the registration is in process.
- HPP is expected to commercialize in Q4FY22.

,				
FY19	FY20	FY21E	FY22E	FY23E
2,776	2,610	2,368	2,840	3,000
15%	-6%	-9%	20%	6%
3,005	3,810	4,503	5,471	7,345
33%	27%	18%	22%	34%
1,983	2,070	1,892	2,284	2,627
34%	4%	-9%	21%	15%
1,779	1,730	2,730	3,100	3,850
-27%	-3%	58%	14%	24%
-	-	-	-	4,143
21.9%	24.8%	26.8%	26.6%	27.0%
	2,776 15% 3,005 33% 1,983 34% 1,779 -27%	2,776         2,610           15%         -6%           3,005         3,810           33%         27%           1,983         2,070           34%         4%           1,779         1,730           -27%         -3%	2,776         2,610         2,368           15%         -6%         -9%           3,005         3,810         4,503           33%         27%         18%           1,983         2,070         1,892           34%         4%         -9%           1,779         1,730         2,730           -27%         -3%         58%	2,776         2,610         2,368         2,840           15%         -6%         -9%         20%           3,005         3,810         4,503         5,471           33%         27%         18%         22%           1,983         2,070         1,892         2,284           34%         4%         -9%         21%           1,779         1,730         2,730         3,100           -27%         -3%         58%         14%


#### Exhibit 7: Segment revenues (standalone)

#### Exhibit 8: Revision in estimates (consolidated)


Rs mn	FY21E			FY22E			FY23E		
	Old	New	% Change	Old	New	% Change	Old	New	% Change
Revenues	11,931	11,931	0.0	14,296	14,296	0.0	20,785	21,565	3.8
EBITDA	3,199	3,199	0.0	3,798	3,798	0.0	5,589	5,815	4.0
EBITDA margins %	26.8	26.8	0bps	26.6	26.6	0bps	26.9	27.0	7.4bps
Net profits	2,260	2,260	0.0	2,748	2,748	0.0	4,155	4,331	4.2
EPS (Rs)	45.7	45.7	0.0	55.5	55.5	0.0	84.0	87.5	4.2

Source: Company, Emkay Research

#### Exhibit 9: PE Band







Source: Company, Emkay Research

Source: Company, Emkay Research

#### Exhibit 11: Peer comparison

Company Name	Price	Mkt Cap	Baaa	TP		PE			PB (x)		E	V/EBITD	4
Company Name	(Rs)	(Rs bn)	Reco	(Rs)	FY20	FY21e	FY22e	FY20	FY21e	FY22e	FY20	FY21e	FY22e
Advanced Enzyme Tech	343	38	Hold	332	29.6	26.8	23.4	4.6	3.9	3.4	18.6	16.8	14.4
Apcotex Industries	167	9	Hold	140	52.2	51.5	28.1	3.4	3.4	3.1	27.1	23.6	15.4
BASF India	1664	72	Buy	1630	389.2	52.1	37.0	5.2	3.7	3.4	33.3	20.1	17.2
Camlin Fine Sciences	121	15	Buy	140	48.5	26.5	16.3	3.7	2.9	2.5	14.4	12.9	9.8
GHCL	198	19	Buy	186	4.7	6.1	4.5	0.9	0.8	0.7	4.2	4.2	3.1
Navin Fluorine	2559	124	Buy	2742	56.0	46.1	29.2	8.0	7.0	5.8	38.8	33.0	21.6
SRF	5343	317	Buy	5466	34.1	28.0	21.2	6.3	4.8	3.9	23.7	16.8	13.0
Tata Chemicals	498	127	Hold	324	1.8	23.3	16.8	1.0	1.0	0.9	10.4	11.6	9.7
Vinati Organics	1155	119	Buy	1330	35.5	42.3	30.6	9.3	8.0	6.6	28.5	31.6	22.7

## Key Financials (Consolidated)

#### **Income Statement**

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	9,959	10,616	11,931	14,295	21,565
Expenditure	7,776	7,981	8,941	10,597	15,921
EBITDA	2,184	2,635	3,199	3,798	5,815
Depreciation	275	370	432	454	592
EBIT	1,908	2,265	2,766	3,344	5,223
Other Income	344	333	500	350	350
Interest expenses	8	20	15	20	20
РВТ	2,244	2,578	3,251	3,674	5,553
Тах	770	802	1,057	926	1,222
Extraordinary Items	(20)	(28)	0	0	0
Minority Int./Income from Assoc.	(17)	(72)	(65)	0	0
Reported Net Income	1,471	1,821	2,260	2,748	4,331
Adjusted PAT	1,491	1,849	2,260	2,748	4,331

#### Balance Sheet

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Equity share capital	99	99	99	99	99
Reserves & surplus	10,626	14,023	15,738	17,942	21,729
Net worth	10,724	14,122	15,837	18,041	21,828
Minority Interest	0	0	0	0	0
Loan Funds	272	465	465	465	465
Net deferred tax liability	0	0	0	0	0
Total Liabilities	10,997	14,587	16,303	18,506	22,293
Net block	4,695	5,676	7,509	10,555	12,963
Investment	4,653	3,297	3,362	3,362	3,362
Current Assets	3,724	7,161	7,270	6,620	9,095
Cash & bank balance	370	2,838	2,882	1,677	1,637
Other Current Assets	0	0	0	0	0
<b>Current liabilities &amp; Provision</b>	2,075	1,547	1,838	2,031	3,127
Net current assets	1,649	5,614	5,431	4,589	5,968
Misc. exp	0	0	0	0	0
Total Assets	10,997	14,587	16,303	18,506	22,293

Cash Flow					
Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
PBT (Ex-Other income) (NI+Dep)	1,900	2,245	2,751	3,324	5,203
Other Non-Cash items	0	0	0	0	0
Chg in working cap	(770)	(1,497)	227	(363)	(1,419)
Operating Cashflow	817	2,914	2,919	2,839	3,504
Capital expenditure	(493)	(1,351)	(2,265)	(3,500)	(3,000)
Free Cash Flow	324	1,563	654	(661)	504
Investments	205	1,356	(65)	0	0
Other Investing Cash Flow	0	0	0	0	0
Investing Cashflow	(308)	(23)	(2,265)	(3,500)	(3,000)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	(111)	193	0	0	0
Dividend paid (incl tax)	386	544	544	544	544
Other Financing Cash Flow	(899)	(968)	(1,153)	(1,088)	(1,088)
Financing Cashflow	(513)	(423)	(609)	(544)	(544)
Net chg in cash	(5)	2,468	45	(1,206)	(40)
Opening cash position	374	370	2,838	2,882	1,677
Closing cash position	370	2,838	2,882	1,677	1,637

Profitability (%)	FY19	FY20	FY21E	FY22E	FY23E
EBITDA Margin	21.9	24.8	26.8	26.6	27.0
EBIT Margin	19.2	21.3	23.2	23.4	24.2
Effective Tax Rate	34.3	31.1	32.5	25.2	22.0
Net Margin	14.8	16.7	18.4	19.2	20.1
ROCE	21.2	20.3	21.1	21.2	27.3
ROE	14.5	14.9	15.1	16.2	21.7
RoIC	34.8	31.4	29.9	28.4	34.0
Per Share Data (Rs)	FY19	FY20	FY21E	FY22E	FY23E
EPS	30.2	37.4	45.7	55.5	87.5
CEPS	35.7	44.8	54.4	64.7	99.5
BVPS	216.9	285.4	320.1	364.6	441.2
DPS	7.8	11.0	11.0	11.0	11.0
Valuations (x)	FY19	FY20	FY21E	FY22E	FY23E
PER	84.9	68.5	56.0	46.1	29.2
P/CEPS	71.7	57.1	47.0	39.5	25.7
P/BV	11.8	9.0	8.0	7.0	5.8
EV / Sales	12.7	11.7	10.4	8.8	5.8
EV / EBITDA	57.9	47.2	38.8	33.0	21.6
Dividend Yield (%)	0.3	0.4	0.4	0.4	0.4
Gearing Ratio (x)	FY19	FY20	FY21E	FY22E	FY23E
Net Debt/ Equity	0.0	(0.2)	(0.2)	(0.1)	(0.1)
Net Debt/EBIDTA	0.0	(0.2)	(0.2)	(0.3)	(0.2
Working Cap Cycle (days)	46.9	95.5	78.0	74.4	73.3
		0010			
Growth (%)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	9.1	6.6	12.4	19.8	50.9
EBITDA	1.6	20.7	21.4	18.7	53.1
EBIT	8.9	18.7	22.1	20.9	56.2
PAT	(18.2)	23.8	24.1	21.6	57.6
Quarterly (Rs mn)	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21
Revenue	2,729	2,605	2,766	2,149	3,189
EBITDA	681	655	688	538	907
			24.9	25.0	28.5
	25.0	25.1			
EBITDA Margin (%)	<b>25.0</b> 473	<b>25.1</b> 454			679
<b>EBITDA Margin (%)</b> PAT	473	454	2,727	560	
EBITDA Margin (%) PAT EPS (Rs)					
EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research	473	454	2,727	560	13.7
EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%)	473 <b>9.6</b>	454 <b>9.2</b>	2,727 <b>55.1</b>	560 <b>11.3</b>	13.7 Sep-20
EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%) Promoters	473 9.6 Sep-19	454 9.2 Dec-19	2,727 55.1 Mar-20	560 11.3 Jun-20	13.7 Sep-20 30.5
EBITDA Margin (%)	473 9.6 Sep-19 31.0	454 9.2 Dec-19 31.0	2,727 55.1 Mar-20 30.5	560 11.3 Jun-20 30.5	679 13.7 Sep-20 30.5 21.1 20.3


Source: Capitaline

#### RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
29-Oct-20	2,275	2,350	12m	Buy	Rohit Sinha
31-Jul-20	1,761	1,925	12m	Buy	Rohit Sinha
18-Jun-20	1,584	1,850	12m	Buy	Rohit Sinha
16-Apr-20	1,437	1,600	12m	Buy	Rohit Sinha
25-Feb-20	1,454	1,600	12m	Buy	Rohit Sinha
07-Feb-20	1,140	1,365	12m	Buy	Rohit Sinha
29-Jan-20	1,246	1,364	12m	Buy	Rohit Sinha
06-Jan-20	980	958	12m	Buy	Rohit Sinha
13-Dec-19	938	958	12m	Buy	Rohit Sinha
24-Oct-19	826	958	12m	Buy	Rohit Sinha
23-Sep-19	762	958	12m	Buy	Rohit Sinha
31-Jul-19	623	860	12m	Buy	Rohit Sinha
07-May-19	678	922	12m	Buy	Amar Mourya
02-Apr-19	751	922	12m	Buy	Amar Mourya
25-Jan-19	642	922	12m	Buy	Amar Mourya
01-Nov-18	639	922	12m	Buy	Amar Mourya
26-Jul-18	649	922	12m	Buy	Amar Mourya
09-Jul-18	647	922	12m	Buy	Amar Mourya
11-May-18	768	922	12m	Buy	Amar Mourya
02-Feb-18	783	922	12m	Buy	Amar Mourya
22-Dec-17	814	982	12m	Buy	Amar Mourya

**RECOMMENDATION HISTORY CHART** 







#### Analyst: Rohit Sinha

#### **Contact Details**

rohit.sinha@emkayglobal.com

#### +91 22 6612 1306 Sector

Speciality Chemicals

#### Analyst bio

Rohit Sinha holds a CFA degree and comes with total four years of experience in the Specialty Chemicals sector. He currently covers nine stocks in the Specialty Chemicals space.

## Emkay Alpha Portfolio – Speciality Chemicals

#### EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Speciality Chemicals	0.20	0.20	-1%	0	100.00
Advanced Enzyme Tech	0.00	0.00	NA	0	1.00
Apcotex Industries	0.00	0.00	NA	0	1.88
BASF India	0.00	0.00	NA	0	0.88
Camlin Fine Sciences	0.00	0.02	NA	2	8.56
GHCL	0.00	0.01	NA	1	4.75
Navin Fluorine	0.00	0.05	NA	5	23.60
Orient Refractories	0.00	0.01	NA	1	3.71
SRF	0.20	0.10	-52%	-10	47.86
Tata Chemicals	0.00	0.01	NA	1	4.02
Vinati Organics	0.00	0.01	NA	1	2.83
Cash	0.00	0.00	NA	0	0.92

Source: Emkay Research

\* Not under coverage: Equal Weight


High Conviction/Strong Over Weight High Conviction/Strong Under Weight

#### Sector portfolio NAV

	Base					Latest
	1-Apr-19	19-Mar-20	18-Jun-20	17-Sep-20	17-Nov-20	17-Dec-20
EAP - Speciality Chemicals	100.0	103.5	128.6	162.8	186.0	202.4
BSE200 Neutral Weighted Portfolio (ETF)	100.0	101.3	128.1	156.2	179.8	196.6

\*Performance measurement base date 1<sup>st</sup> April 2019

#### **NAV** chart



Source: Emkay Research

#### Please see our model portfolio (Emkay Alpha Portfolio): Nifty

#### Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

Source: Emkay Research

#### **Emkay Rating Distribution**

Expected Return within the next 12-18 months.
Over 15%
Between -5% to 15%
Below -5%
Ov Bet

Completed Date: 18 Dec 2020 15:08:22 (SGT) Dissemination Date: 18 Dec 2020 15:09:22 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

**Disclaimer for U.S. persons only:** This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of December 18, 2020
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of December 18, 2020.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the December 18, 2020
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the December 18, 2020

RESTRICTIONS ON DISTRIBUTION	
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 <sup>th</sup> Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

#### Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com